AbCellera Biologics (ABCL) Non Operating Income: 2020-2023
Historic Non Operating Income for AbCellera Biologics (ABCL) over the last 4 years, with Dec 2023 value amounting to $17.5 million.
- AbCellera Biologics' Non Operating Income rose 174.13% to $17.5 million in Q4 2023 from the same period last year, while for Dec 2023 it was $63.2 million, marking a year-over-year increase of 179.70%. This contributed to the annual value of $114.4 million for FY2024, which is 81.03% up from last year.
- Latest data reveals that AbCellera Biologics reported Non Operating Income of $17.5 million as of Q4 2023, which was up 11.77% from $15.6 million recorded in Q3 2023.
- In the past 5 years, AbCellera Biologics' Non Operating Income registered a high of $17.5 million during Q4 2023, and its lowest value of -$13.5 million during Q4 2020.
- In the last 3 years, AbCellera Biologics' Non Operating Income had a median value of $6.1 million in 2022 and averaged $8.4 million.
- As far as peak fluctuations go, AbCellera Biologics' Non Operating Income tumbled by 69.56% in 2022, and later skyrocketed by 786.42% in 2023.
- AbCellera Biologics' Non Operating Income (Quarterly) stood at -$13.5 million in 2020, then soared by 123.43% to $3.2 million in 2021, then soared by 101.65% to $6.4 million in 2022, then soared by 174.13% to $17.5 million in 2023.
- Its Non Operating Income stands at $17.5 million for Q4 2023, versus $15.6 million for Q3 2023 and $13.4 million for Q2 2023.